Key Drivers
- Margin resilience
- Leverage pressure
- Cash burn
AIAI Summary
XRAY should be viewed as a turnaround/repair story, not a growth compounder: the upside now depends on management delivering the $120M cost reset, converting positive operating cash flow into sustained free cash flow, and proving execution on new products/channels before heavy debt and weak price action overwhelm the thesis.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin resilience
- •Leverage pressure
- •Cash burn
XRAY is improving operationally with near-breakeven quarterly results and solid gross margins, but persistent leverage, declining cash, and negative free cash flow keep the turnaround and valuation story cautious.
Price Behavior
Key Price Behavior Insights:
- •Lower-high pattern
- •Broken support
- •Near oversold
XRAY has been in a clear downtrend over the last month, falling about 20% to a period low after failed rebounds and a break below $11.00, with the setup still bearish unless it reclaims $11.00 and then $11.37.
Fell about 20% from $12.51 to $10.07 and closed at the lowest point in the look-back window
Sentiment & News
Key News Insights:
- •Margin Pressure
- •Product Launches
- •Debt Focus
DENTSPLY SIRONA's Q1 2026 results missed expectations on earnings and margins amid tariff pressure and U.S. softness, even as it expanded product launches and distribution while shifting capital allocation toward debt reduction.
ക
The update is likely to pressure XRAY near term, with sentiment driven more by margin recovery and execution than by recent commercial expansion
Similar Companies in Healthcare
Other companies in the same sector with AI ratings